Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 3/20 | 0.69 |
| ▸ | DRD4 | P21917 | 11/20 | 0.66 |
| ▸ | DRD2 | P14416 | 11/20 | 0.66 |
| ▸ | HTR1A | P08908 | 4/20 | 0.66 |
| ▸ | DRD3 | P35462 | 3/20 | 0.66 |
| ▸ | HTR2A | P28223 | 3/20 | 0.66 |
| ▸ | HTR2C | P28335 | 2/20 | 0.66 |
| ▸ | HRH1 | P35367 | 2/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.60 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.60 |
| ▸ | DRD1 | P21728 | 1/20 | 0.60 |
| ▸ | HTR2B | P41595 | 1/20 | 0.60 |
| ▸ | HTR6 | P50406 | 1/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.60 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7949281 | 0.88 | CACNA1G (0.69) | CACNA1GDRD4DRD2HTR1ADRD3 | |
| SCHEMBL6368839 | 0.87 | CACNA1G (0.60) | CACNA1GDRD4DRD2HTR1ADRD3 | |
| SCHEMBL3197065 | 0.86 | CACNA1G (0.52) | CACNA1GDRD4DRD2HTR1ADRD3 | |
| SCHEMBL2386501 | 0.86 | GFER (0.54) | CACNA1GDRD4DRD2HTR1ADRD3 | |
| SCHEMBL3197900 | 0.85 | HTR1A (0.66) | CACNA1GDRD4DRD2HTR1ADRD3 | |
| SCHEMBL3207003 | 0.84 | HTR1A (0.67) | CACNA1GDRD2HTR1ADRD3HTR2A | |
| SCHEMBL3187888 | 0.84 | KCNH2 (0.74) | CACNA1GDRD4DRD2HTR1AHTR2A | |
| SCHEMBL18754269 | 0.84 | KDM4E (0.75) | CACNA1GDRD4DRD2HTR1ADRD3 | |
| SCHEMBL8608402 | 0.83 | SMN1; SMN2 (0.71) | CACNA1GDRD4DRD2HTR1ADRD3 | |
| SCHEMBL4400390 | 0.83 | SMN1; SMN2 (0.66) | DRD4HTR1AKDM4EHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | CACNA1G 245/4885DRD4 26/4885DRD2 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.